Avosentan for Overt Diabetic Nephropathy
March 3rd, 2010
The study was terminated early because of excess cardiac events. They did not find any difference in mortality or rate of progression between the two groups. Doesn’t look like a winner.
“Avosentan reduces albuminuria when added to standard treatment in people with type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure.”